Search
Spero Therapeutics Inc
SPROAdd to Watchlist
2.280USD
+0.170+8.06%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
132.02MMarket Cap
8.21P/E TTM
Financial Health
Currency: USD Updated: 2026-06-18 The current financial score of Spero Therapeutics Inc is 7.39, ranking 121 out of 389 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 258.00K, representing a year-over-year decrease of 95.61%, while its net profit experienced a year-over-year decrease of 48.05%.
Financials
10.00
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
4.67
Total revenue
Operating profit
Total assets
SG&A
Relevant data have not been disclosed by the company yet.
Operational Efficiency
10.00
Cash flow from operating activities
Income after tax
Relevant data have not been disclosed by the company yet.
Growth Potential
5.04
Cash flow from operating activities
Total revenue
Relevant data have not been disclosed by the company yet.
Shareholder Returns
7.25
Free cash flow
Relevant data have not been disclosed by the company yet.
